Here, we show that the BH3-only mimetic, ABT-737, has two properties: one, it can overcome resistance to immunotoxin-mediated apoptosis; and two, it can increase immunotoxin delivery from the ER to the cytosol resulting in enhanced killing by as much as 20-fold. Both activities were achieved using concentrations (3 or 10 μmol/L) of ABT-737 that were nontoxic when added alone. Combinations of immunotoxin and ABT-737 were effective at overcoming resistance because each agent targeted a distinct Bcl-2 family member. By inhibiting protein synthesis, immunotoxin treatment promotes a decline in Mcl-1 levels. This was reported previously for both cycloheximide (27) and PE immunotoxins (26), and was confirmed here. ABT-737 is a peptide mimetic modeled on a BH3-only domain and exhibits high binding affinity binding for Bcl-2, Bcl-xl, and Bcl-w (19). Binding of ABT-737 to either Bcl-2 or Bcl-xl neutralizes their prosurvival activity, allowing Bax or Bak to initiate the intrinsic arm of the apoptosis ...
Selective elimination of B7H-expressing tumor cells by transgenic T cells in vivo. J558-Neo and J558-B7H were mixed at 1:1 ratio and injected into the flank of
Immunotoxins are proteins that contain a toxin along with an antibody or growth factor that binds specifically to target cells. Nearly all protein toxins work b...
In this report we demonstrate that human α2-macroglobulin (α2M) reacts with deglycosylated ricin A chain (dgA) and its immunotoxins to form high molecular weight complexes (molecular mass approximately 800 kDa). This interaction has a t1/2 at 37°C of 5 h and reaches completion at 24 h. Complexes of α2M-dgA cannot be dissociated by guanidine, sodium dodecyl sulfate, or low pH, but can be partially dissociated by reducing agents, such as 2-mercaptoethanol in the presence of sodium dodecyl sulfate. This indicates that dgA or dgA-containing immunotoxins are bound to α2M by disulfide bonds. The dgA-binding site on α2M and the mechanism underlying its interaction with dgA are different from those described for proteases or methylamine. α2M complexes do not bind to Blue-Sepharose 4B or anti-A chain-Sepharose, suggesting that the sites on dgA which bind Cibacron Blue or polyclonal anti-A chain antibodies are sterically blocked or modified by interaction with α2M. The interaction of α2M with dgA ...
B3(Fv)-PE38KDEL recombinant immunotoxin: composed of the heavy chain V(H) region of the carcinoma specific Mab B3 connected by a flexible linker peptide to the corresponding light chain V(L) which is in turn fused to a truncated form of Pseudomonas exotoxin
PubMed Central Canada (PMC Canada) provides free access to a stable and permanent online digital archive of full-text, peer-reviewed health and life sciences research publications. It builds on PubMed Central (PMC), the U.S. National Institutes of Health (NIH) free digital archive of biomedical and life sciences journal literature and is a member of the broader PMC International (PMCI) network of e-repositories.
Learn the latest mesothelioma treatment news related to a team of molecular biologists and researchers at the National Cancer Institute (NCI) and Fukishima University (Fukishima U) that has developed
Therapy of lymphomas with immunotoxins comprised of soluble T-cell receptors conjugated to ricin A-chain.. Immunotoxins are conjugates of cell-binding moieties linked to toxins or toxin subunits. Many investigators have used antibodies directed against tumor specific-antigens as the cell- binding moiety. B-cell tumors are ideal for this type of therapy because of their tumor-specific idiotype (Id). However, B-cell tumors often secrete Id which competes with tumor cells for binding of anti-Id antibodies. Therefore, to overcome this obstacle, my research focuses on developing soluble T-cell receptors (TCR) from tumor specific T cell clones as the cell-binding moiety, and ricin-A chain as the toxic moiety. T-cells recognize cell-bound (but not soluble) antigen in association with products of the major histocompatibility complex. Therefore, free idiotype should not interfere with binding of soluble TCRs to tumor cells. Id specific T-cells have been cloned from mice immunized with the murine tumor, ...
Immunotoxins are targeted anticancer therapeutics that kill cancer cells using a cytotoxic bacterial toxin payload. Their development for use in solid tumor malignancies was delayed due to issues with their immunogenicity and limited therapeutic window. However, new research has rejuvenated the field. Coadministration with a lymphocyte-depleting regimen of pentostatin and cyclophosphamide can delay antidrug antibody formation, increasing the number of treatment cycles that patients can receive and resulting in durable responses in heavily pretreated patients. In addition, a new generation of immunotoxin molecules with reduced immunogenicity and nonspecific toxicity has been developed through protein engineering techniques, and one has recently entered the clinic. In preclinical studies in mouse models, these new agents are effective against many tumor types as single agents, and also produce synergistic antitumor responses in combination with chemotherapy. These new immunotoxins have renewed ...
The global Immunotoxins market is valued at USD XX million in 2016 and is expected to reach USD XX million by the end of 2022, growing at a CAGR of XX% between 2016 and 2022
A phase I protocol has been initiated to investigate the treatment related toxicity of immunotoxin treatment with an antibody targeted to the epithelial cell marker EGP2 (ESA/Ep-CAM), conjugated to pseudomonas exotoxin A (PE). A total of 27 patients with antigen positive epithelial tumors were treated with up to 8 injections of the immunoconjugate, given every second week. On the currrent dose level, 6.5 ng/kg, one patient experienced dose limiting toxicity (DLT), a grade 4 elevation in liver enzymes after the first administration of the immunotoxin. No other serious adverse events have been associated with the study treatment ...
Increased understanding of the precise molecular mechanisms involved in cell survival and cell death signaling pathways offers the promise of harnessing these molecules to eliminate cancer cells without damaging normal cells. Tyrosine kinase oncoproteins promote the genesis of leukemias through both increased cell proliferation and inhibition of apoptotic cell death. Although tyrosine kinase inhibitors, such as the BCR-ABL inhibitor imatinib, have demonstrated remarkable efficacy in the clinic, drug-resistant leukemias emerge in some patients because of either the acquisition of point mutations or amplification of the tyrosine kinase, resulting in a poor long-term prognosis. Here, we exploit the molecular mechanisms of caspase activation and tyrosine kinase/adaptor protein signaling to forge a unique approach for selectively killing leukemic cells through the forcible induction of apoptosis. We have engineered caspase variants that can directly be activated in response to BCR-ABL. Because we ...
The success rate of chemotherapy in cancer treatment is limited. Tumors can be intrinsically resistant or acquire resistance during treatment with cytostatic drugs. In these cases, other therapies like immunotherapy may be useful. Most immunotoxins, composed of either a monoclonal antibody or another tumor cell-binding ligand, and a toxin, like PE, are proteins of rather large size and do not resemble the classical chemical structures of substrates of drug pumps like Pgp and the MRP proteins. Therefore, they may be good alternatives or additives to conventional chemotherapy.. A number of studies reported on the effects of immunotoxins on drug-resistant, primarily Pgp-overexpressing, cells with some conflicting results. Some reported a beneficial effect of an immunotoxin alone or in combination with conventional drugs in cell kill of MDR tumor cells (36, 37, 38) . Others argue for using immunotoxins in combination with primary conventional chemotherapy before drug resistance develops, because an ...
Dr. Onda is focusing on the pre-clinical development of recombinant immunotoxins (RITs) as new immunotherapy reagents. RITs are genetically modified forms of Pseudomonas exotoxin A that are targeted to cancer cells by the Fv portion of antibodies. These RITs are now in clinical trials and have produced many complete remissions in cancer. As a staff scientist, Dr. Onda uses protein engineering to make these proteins more useful in patients by decreasing their immunogenicity so more treatment cycles can be given before antibodies develop in the patients. New RITs were designed by identifying and silencing the major B cell epitopes. These new RITs are being developed for clinical trials.. ...
Since its development in 1975, monoclonal antibody (mAb) technology has greatly enhanced our ability to analyse complex antigenic systems as well as improve the sensitivity and speed of many diagnostic tests. In particular, the study of tumour associated antigens using mAbs have revealed that many transformed cell phenotypes have useful markers on their plasma membrane, cytoplasm, or as secreted forms which can be used in developing diagnostic assays. Therapeutic application of these anti-tumour mAbs has however, been slow relative to the research and diagnostic applications. This article will discuss how the therapeutic effectiveness of anti-tumour mAbs can be enhanced by coupling them to drugs, toxins or radionucleids; and review the current advances and problems related to the application of these mAb conjugates ...
Dual B- and T-cell de-immunization of recombinant immunotoxin targeting mesothelin with high cytotoxic activity. See Mazor et al.
TY - JOUR. T1 - B-cell restricted saporin immunotoxins. T2 - Activity against B-cell lines and chronic lymphocytic leukemia cells. AU - Bregni, M.. AU - Siena, S.. AU - Formosa, A.. AU - Lappi, D. A.. AU - Martineau, D.. AU - Malavasi, F.. AU - Dorken, B.. AU - Bonadonna, G.. AU - Gianni, A. M.. PY - 1989. Y1 - 1989. N2 - B cell-restricted immunotoxins were constructed by conjugating anti-B monoclonal antibodies to saporin, the major ribosome inactivating protein from the seeds of the plant Saponaria officinalis. HD37-SAP is directed against CD19, the broadest B cell-specific determinant. HD39-SAP and HD6-SAP recognize two different epitopes on the CD22 molecule, an antigen present on the cell surface of B cells at late stages of differentiation. All three immunotoxins inhibited DNA synthesis and protein synthesis in target B lymphoma cells with a dose-related effect, in short incubation times and in the absence of potentiators. A clonogenic assay demonstrated that all immunotoxins could ...
Many epithelial cancers rely on enhanced expression of the epidermal growth factor receptor (EGFR) to drive proliferation and survival pathways. Development of therapeutics to target EGFR signaling has been of high importance, and multiple examples have been approved for human use. However, many of the current small molecule or antibody-based therapeutics are of limited effectiveness due to the inevitable development of resistance and toxicity to normal tissues. Recombinant immunotoxins are therapeutic molecules consisting of an antibody or receptor ligand joined to a protein cytotoxin, combining the specific targeting of a cancer-expressed receptor with the potent cell killing of cytotoxic enzymes. Over the decades, many bacterial- or plant-based immunotoxins have been developed with the goal of targeting the broad range of cancers reliant upon EGFR overexpression. Many examples demonstrate excellent anti-cancer properties in preclinical development, and several EGFR-targeted immunotoxins have
PRIMARY OBJECTIVES:. I. To define the maximum tolerated dose (MTD) of Combotox (deglycosylated ricin A chain-conjugated anti-CD19/anti-CD22 immunotoxins) when added to high-dose cytarabine during salvage therapy for adult patients with relapsed or refractory B-lineage acute lymphoblastic leukemia.. SECONDARY OBJECTIVES:. I. To evaluate the efficacy of this regimen. II. To assess for the presence of a postulated CD34+/CD38-/low/CD19+ leukemic stem cell phenotype in the bone marrow at time of relapse and to assess its association with treatment outcome.. III. To determine the development of human mouse or ricin antibodies (human anti-mouse antibodies [HAMA]/human anti-ricin antibodies [HARA]).. IV. To determine the pharmacokinetic characteristics of Combotox. V. To evaluate the value of fractional excretion of sodium (FeNa) as early marker of toxicity.. OUTLINE: This is a dose-escalation study of deglycosylated ricin A chain-conjugated anti-CD19/anti-CD22 immunotoxins.. Patients receive high-dose ...
Immunotoxin Therapy for Mesothelioma Malignant Mesothelioma Tumor of pleura or peritoneum About 3,000 new cases in US each year Limited treatment options and poor prognosis Mesothelioma arises at sites
TY - JOUR. T1 - Crystal structure of the disulfide-stabilized Fv fragment of anticancer antibody B1. T2 - Conformational influence of an engineered disulfide bond. AU - Almog, Orna. AU - Benhar, Itai. AU - Vasmatzis, George. AU - Tordova, Maria. AU - Lee, Byungkook. AU - Pastan, Ira. AU - Gilliland, Gary L.. PY - 1998/5/1. Y1 - 1998/5/1. N2 - A recombinant Fv construct of the B1 monoclonal antibody that recognizes the Lewis(Y)-related carbohydrate epitope on human carcinoma cells has been prepared. The Fv is composed of the polypeptide chains of the V(H) and V(L) domains expressed independently and isolated as inclusion bodies. The Fv is prepared by combining and refolding equimolar amounts of guanidine chloride solubilized inclusion bodies. The Fv is stabilized by an engineered interchain disulfide bridge between residues V(L)100 and V(H)44. This construct has a similar binding affinity as that of the single-chain construct (Benhar and Pastan, Clin. Cancer Res. 1:1023-1029, 1995). The B1 ...
Background: About 80% of patients with hairy cell leukemia (HCL) have malignant cells that express CD25 (Tac or IL2Ra). Normal resting B- and T-cells do not express CD25. LMB-2 is an anti-CD25 recombinant immunotoxin containing variable domains of MAb anti-Tac and truncated Pseudomonas exotoxin. A phase I trial at NCI found that the MTD of LMB-2 was 40 microg/Kg IV given every other day for 3 doses (QOD x3). The most common adverse events were transient fever, hypoalbuminemia and transaminase elevations. In that trial, 4 of 4 patients with chemoresistant HCL had major responses, including one complete (CR) and 3 partial remissions. The patient with CR entered the trial transfusion dependent and now still has normal hemoglobin and platelet counts over 7 years later. Because HCL is more frequently CD22+ than CD25+ (100 vs 80%), HCL patients were subsequently treated with the anti-CD22 recombinant immunotoxin BL22 and no further HCL patients were treated with LMB-2. BL22 has induced 25 CRs out of ...
Blast cells from patients with acute myeloid leukemia (AML) commonly express CD64, the high-affinity receptor for immunoglobulin G (FcgammaRI). An immunotoxin (MDX-44) was constructed by coupling humanized anti-CD64 monoclonal antibody (mAb) H22 via a bivalent linker to deglycosylated ricin A-chain (RA). Human leukemia cell lines were incubated with MDX-44 or H22/free RA. The effect of MDX-44 on the proliferation of leukemia cells was assessed by [(3)H]thymidine incorporation. In the presence of interferon-gamma (IFN-gamma), MDX-44 significantly inhibited the proliferation of CD64(+) HL-60, NB4, and U937 cells in 72-h cultures in a dose-dependent manner. The mechanism of action appeared to be the induction of apoptosis, as measured by propidium iodide staining and flow cytometry analysis. However, CD64(-) KG-1a and Daudi cells were not affected by MDX-44/IFN-gamma. Incubating HL-60 cells with MDX-44/IFN-gamma resulted in a 99% decrease in colony-forming units, whereas colony-forming cells
TY - JOUR. T1 - Emergence of immunoglobulin variants following treatment of a B cell leukemia with an immunotoxin composed of antiidiotypic antibody and saporin. AU - Glennie, M. J.. AU - McBride, H. M.. AU - Stirpe, F.. AU - Thorpe, P. E.. AU - Worth, A. T.. AU - Stevenson, G. T.. PY - 1987. Y1 - 1987. N2 - The potency and specificity of immunotoxins consisting of monoclonal antiidiotype conjugated to the ribosome-inactivating protein, saporin, have been evaluated in the treatment of guinea pig L2C B lymphocytic leukemia. The immunotoxins were therapeutically much more effective than their parent antibodies. Their specificity reflected that of their antiidiotype component. Although the leukemia emerged eventually in most animals treated with these conjugates, most of the cells showed altered Ig expression, which rendered them resistant to the therapy. Commonly, the emerging cells had lost μ heavy chain production, leaving them negative for intracellular, surface, and secreted IgM, but still ...
Ricin A chain-containing immunotoxins (IT-As) specific for the human B-cell antigens, CD22 and CD19, were constructed using the monoclonal antibodies, HD6 and HD37, respectively. IT-As were prepared by coupling intact antibodies, F(ab′)2, or Fab fragments to native or chemically deglycosylated ricin A chain. The IT-As were then evaluated for cytotoxicity to normal and neoplastic human B-cells in vitro with the major objective of appraising their suitability for in vivo therapy of human B-cell tumors. The IT-As prepared with both the HD6 and HD37 antibodies were specifically toxic to normal B-cells and to most of the neoplastic B-cell lines tested. However, the IT-As prepared from HD6 were generally more potent than those prepared from HD37. On Daudi cells, to which the two antibodies bound in similar numbers and with similar affinities, IT-As prepared with intact HD6 antibody or its Fab fragment were 10-fold and 1.5- to 4-fold more potent, respectively, than the corresponding HD37 IT-As. The ...
Immunoconjugates for the selective delivery of a cytokine to a target cell are disclosed. The immunoconjugates are comprised of an immunoglobulin heavy chain having a specificity for the target cell, such as a cancer or virus-infected cell, and a cytokine, such as lymphotoxin, tumor necrosis factor alpha, interleukin-2, or granulocyte-macrophage colony stimulating factor, joined via Aits amino terminal amino acid to the carboxy-Aterminus of the immunoglobulin. Nucleic acid sequences encoding these immunoconjugates and methods of their preparation by genetic engineering techniques are also disclosed.
Monoclonal antibody RFB4-ricin chain A conjugate is an immunotoxin that is comprised of deglycosylated ricin chain A (dgA) coupled to the murine IgG1 anti-CD22
Sampling of small molecules from both porous and non-porous surfaces poses a significant challenge across biological agents. Particle sizes of toxins are smaller than living organisms and can be extremely toxic at low level concentrations. A small number of studies evaluating sampling efficiencies of commercial off the shelf (COTS) materials have been performed with toxins and proteins. However, they have been limited to non-ricin stimulants with drastically different physical properties than their native counterparts. We have identified a commercially available non-toxic recombinant ricin, complete with both A and B subunits present, which can be recognized by antibodies commonly used to assay native ricin. In evaluating recovery efficiency, we deposited the recombinant ricin by both liquid deposition, and as a dry aerosol. Our studies demonstrated a significant difference in recovery efficiencies from liquid deposited ricin, ranging between 30% and 70%, than from an aerosol generated deposition
Welcome to Biosensis, providing quality life-science reagents that work. We specialise in antibodies for Neuroscience, Stem Cells and Autophagy research, and have a growing range of antibodies that have proved valuable in the study of Alzheimers and Parkinsons diseases, Immunology and Obesity.. In addition to antibodies, we have a wide range of ELISA kits that are ideal for the quantification of target antigens in tissue extracts, serum and cell culture.. Founded and run by researchers, our staff understand the issues faced by scientists at the bench. That is why we only offer antibodies that have been tested under real experimental conditions. Our staff and advisors have many years of experience in the manufacture and use of antibodies for a wide range of techniques including western blot, immunohistochemistry, FACS analysis, real time imaging with confocal microscopy, biological inhibition and antibody cloning. With a combined 340+ peer reviewed research publications, Biosensis staff are ...
Fingerprint Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint. ...
The National Cancer Institutes new clinical trial involves immunotoxins. Read how play-by-play immunotherapy treatments may help treat mesothelioma.
HRP偶联Saporin抗体(ab42903)经WB, IHC实验严格验证,被4篇文献引用,实验条件参看说明书。Abcam对所有产品均提供质保服务和专属技术支持,中国75%以上现货。
Summary of Facts and Submissions. I. European patent application No. 93 912 143.0 relating to immunotoxins directed against CD33 related surface antigens, is based on international application PCT/US 93/03284, which was published as WO 93/20848 with 21 claims.. II. The application had been refused by the examining division on the grounds that the subject-matter of claims 1, 10 and 18 filed during oral proceedings did not meet the requirements of Article 56 EPC.. III. An appeal was lodged against this decision. The Statement of Grounds of Appeal comprised a main request, a first and a second auxiliary requests.. IV. In a communication expressing its provisional, non-binding opinion on the issues to be discussed, the board expressed doubts, inter alia, as to whether the application provided sufficient information enabling the skilled person to arrive at the recombinant gelonin referred to in claim 2 of all requests then on file which read:. 2. A composition according to claim 1, characterized in ...
Development of cancer treatment regimens including immunotoxins is partly hampered by their immunogenicity. Recently, deimmunized versions of toxins have been described, potentially being better suited for translation to the clinic. In this study, a recombinant tripartite fusion toxin consisting of a deimmunized version of exotoxin A from Pseudomonas aeruginosa (PE38) genetically fused to an affibody molecule specifically interacting with the human epidermal growth factor receptor 2 (HER2), and also an albumin binding domain (ABD) for half-life extension, has been produced and characterized in terms of functionality of the three moieties. Biosensor based assays showed that the fusion toxin was able to interact with human and mouse serum albumin, but not with bovine serum albumin and that it interacted with HER2 (K-D=5 nM). Interestingly, a complex of the fusion toxin and human serum albumin also interacted with HER2 but with a somewhat weaker affinity (K-D=12 nM). The IC50-values of the fusion ...
Ribosome-inactivating proteins (RIPs) certainly are a category of plant toxins that permanently damage ribosomes and perhaps other mobile substrates, causing cell death thus. efficient eliminating of focus on cells. This review summarizes saporin-S6-including conjugates and their software in tumor therapy, taking into consideration and research both in pet versions and in medical trials. The examine can be structured based on the focusing on of hematological solid tumors and on the antigen identified for the cell surface area. and research both in pet versions and in medical trials. Conjugates including antibodies or their fragments are known as immunotoxins (It is), whereas conjugates having additional companies are denoted as conjugates. Unless specified otherwise, the conjugates as well as the It is detailed in this review have already been obtained by chemical substance conjugation. 2. It is Focusing on Hematological Cells Hematological cells have already been extensively researched and ...
RATIONALE: Immunotoxins such as denileukin diftitox can locate cancer cells and kill them without harming normal cells. This may be an effective treatme
Our research program involves studies in chemistry, biology, and medicine. We place special emphasis on both the design of novel therapeutic drug candidates, and the development of new strategies for the efficient synthesis and evaluation of these molecules. The research supported by this grant is focused on molecules that are selected because of their unique biological activities and consequently their potential to lead to new therapeutics for treating cancer and other diseases.. One part of this program is directed at bryostatin, a marine natural product that is now in human clinical trials. Bryostatin has a unique range of activities, including the ability to trigger a programmed cell death pathway called "apoptosis" in cancer cells, providing a means to achieve selective elimination of cancer cells in the presence of normal cells. Bryostatin also reverses a cellular process called "multidrug resistance" that can allow cancer cells to neutralize the effects of entire classes of drugs; ...
Transferrin Receptor小鼠单克隆抗体[B-G24](ab47094)可与人样本反应并经Flow Cyt实验严格验证。所有产品均提供质保服务,中国75%以上现货。
BIOLOGICAL FLUID FILTRATION UNIT PROVIDED WITH AN OFFSET INLET AND/OR OUTLET MEMBER - A filtration unit intended to allow the selective elimination of target substances from a fluid such as flood or a blood component, has an outer envelope formed from two flexible sheets joined together over their periphery along a bond line so as to define an inner volume, the envelope containing a filtering medium which delimits, on both sides of the bond line, an inlet compartment of the fluid to be filtered and an outlet compartment of the filtrate, each of the compartments being provided with an element-respectively an inlet and outlet element-for bringing the compartment into communication with the outside, the elements being connected between the sheets and comprising a flow channel that passes through the bond line, the unit being characterized in that at least one channel is offset relative to the bond line towards the compartment with which the channel is in communication ...
Epidemiological studies show that individuals exposed to repeated stress, a major trigger of depression, increase their caffeine intake, which correlates inversely with the incidence of depression. However, the mechanism underlying this protective effect is unknown. We used an animal model of chronic unpredictable stress (CUS) to show that caffeine prevents the maladaptive changes caused by CUS in a manner mimicked by the selective blockade of adenosine A2A receptors (A2AR). CUS enhanced A2AR in synapses, and the selective elimination of neuronal A2AR abrogated CUS modifications. Moreover, A2AR blockade also afforded a therapeutic benefit, paving the way to consider A2AR blockers as a strategy to manage the negative impact of chronic stress on mood and memory ...
Juan Carlos Izpisua Belmontes group published a Cell paper today on using gene editing to reverse mutations associated with human mitochondrial disease. The paper is Reddy, et al. and is entitled, "Selective Elimination of Mitochondrial Mutations in the Germline by […]. ...
ウサギ・ポリクローナル抗体 ab84036 交差種: Ms,Hu 適用: WB,IHC-FrFl,ICC/IF…Transferrin Receptor抗体一覧…画像、プロトコール、文献などWeb上の情報が満載のアブカムの Antibody…
ウサギ・ポリクローナル抗体 ab124209 交差種: Hu 適用: WB…Transferrin Receptor抗体一覧…画像、プロトコール、文献などWeb上の情報が満載のアブカムの Antibody 製品。国内在庫と品質保証制度も充実。
Use of the selective immunotoxin; 192 IgG-saporin, is helping to elucidate the role of the cholinergic system in cognition by overcoming the problems of interpretation associated with the use of non-specific lesioning agents. In separate studies, we have compared the long- and short-term effects of …
Patients with CD22(+) B-cell lymphomas will be treated with escalating doses as a 192 hr infusion of immunotoxin in a Phase I study to determine dose li
Some types of cancers are more difficult to treat than others, and to date, there is no general accepted standard approach how to treat pancreatic cancer. The aim of this project was to. construct an immunotoxin with an affinity towards pancreatic cancer cells. The idea is that the coupling of a scFv antibody to a toxin will improve tumor selectivity of a drug that is too toxic to be used on its own, as well as to confer cell killing power to the scFv antibody that is tumor-specific but not sufficiently cytotoxic.. A naïve phage scFv library was screened with the CBASTM method and the tumor cell line specific polyclonal mixture, obtained from the panning, was cloned into the cloning vector pHOG21 and expressed in E. coli. 6000 clones were randomly picked and after characterization and DNA fingerprinting, 96 promising clones where chosen for further. characterization. Of these 96 clones, 85 % were obtained from panning at 37 °C, supporting the hypothesis that the CBASTM method preferentially ...
SS1P is an immunotoxin developed as a treatment for mesothelioma patients at the National Cancer Institute. It may cause regression of tumors.
References for Abcams Anti-Transferrin Affibody® Molecule (ab31910). Please let us know if you have used this product in your publication
Antibody-drug conjugates (ADCs) have the potential to elicit an immune response that could impact their PK, efficacy, and safety.
The report reviews the competitive landscape and pipeline of antibody-drug conjugates and analyzes R&D stage, targets and drug payloads of ADCs as well as company portfolios.